# US 2025/0049932 A1 · Cytotoxicity targeting chimeras for folate receptor-expressing cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049932 A1
- Document ID: US20250049932A1
- Status: Published application
- Kind: A1
- Application number: 18/808,367
- Filed: 2024-08-19
- Published: 2025-02-13
- Earliest claimed: 2022-02-25
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: Glaxosmithkline Intellectual Property Development Limited
- Inventors: Christina Ng Di Marco; Matthew Robert Sender; Brandon James Turunen
- Web page: https://patentgrep.com/patent/US20250049932A1

## CPC

- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61P 35/00: Antineoplastic agents
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is C1-4 alkyl or C3-6 cycloalkyl;
L is a divalent linker of Formula (L-a) or (L-e):
or a stereoisomer thereof,
wherein:
Ring A and Ring B are each independently C4-6 cycloalkylene;
L1a is C3-5 linear alkylene, wherein 1 or 2 methylene units are replaced with —O— or —NRa—;
each Ra is independently hydrogen or C1-3 alkyl; and
L2a is —O—, —NHC(O)—, or —CH2—O—; or
wherein n is an integer of 3 to 50;
wherein each
represents a covalent bond to the Y group of Formula (I), or when Y is a bond, a covalent bond to the C(O) group of Formula (I), and each
represents a covalent bond to the methylene group of Formula (I); and
Y is a bond or a divalent spacer moiety of one to twelve atoms in length.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is —CH3.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-i):
or a stereoisomer thereof,
wherein Ring A, L1a, L2a,
and
are as defined for Formula (L-a).

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-ii):
or a stereoisomer thereof,
wherein L1a, L2a,
and
are as defined for Formula (L-a); p is 1 or 2; and m is 1 or 2.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-iii):
or a stereoisomer thereof,
wherein p is 1 or 2; m is 1 or 2; n is 1, 2, or 3; and
are as defined for Formula (L-a).

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a) selected from the group consisting of:

### Claim 7 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein Y is selected from a bond; —NH—; —(C1-12 alkylene)-, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —C(O)—, —NHC(O)—, —C(O)NH—, —(C3-6 cycloalkylene)-, —(C3-6 cycloalkenylene)-, 3- to 6-membered heterocycloalkylene, arylene, or heteroarylene; or —(C2-12 alkenylene)-, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —C(O)—, —NHC(O)—, —C(O)NH—, —(C3-6 cycloalkylene)-, —(C3-6 cycloalkenylene)-, 3- to 6-membered heterocycloalkylene, arylene, or heteroarylene.

### Claim 8

(canceled)

### Claim 9 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of:

### Claim 10 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein Y is

### Claim 11

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A method of treating and/or preventing a disease or disorder in a patient in need thereof, the method comprising: administering to the patient a therapeutically effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the disease or disorder is selected from a cancer, an inflammatory disease, or an autoimmune disease.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease or disorder is mediated by folate receptor α (FRα) and/or folate receptor β (FRβ) and/or is associated with FRα- and/or FRβ-positive pathogenic cells.

### Claim 14 (depends on 12)

The method of claim 12, wherein the disease is a cancer that is a solid tumor.

### Claim 15 (depends on 12)

The method of claim 12, wherein the disease or disorder is a cancer selected from leukemia, lymphoma, lung cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), cervical cancer, head and neck cancer, pancreatic cancer, prostate cancer, ovarian cancer, endometrial cancer, renal cancer, brain cancer, gastric cancer, endocrine cancer, testicular cancer, bladder cancer, or breast cancer.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of increasing antibody-dependent cell cytotoxicity (ADCC) of FRα- and/or FRβ-expressing cells, the method comprising: contacting the cells with an effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the FRα- and/or FRβ-binding moiety of the compound binds the FRα and/or FRβ expressed on the cells.

### Claim 19 (depends on 1)

A method of depleting FRα- and/or FRβ-expressing cells, the method comprising: contacting the cells with an effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the FRα- and/or FRβ-binding moiety of the compound binds the FRα and/or FRβ expressed on the cells.

### Claim 20

(canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a CDR1 having SEQ ID NO: 1, a CDR2 having SEQ ID NO: 2, and a CDR3 having SEQ ID NO: 3, and the light chain comprising a CDR1 having SEQ ID NO: 4, a CDR2 having SEQ ID NO: 5, and a CDR3 having SEQ ID NO: 6.

### Claim 22 (depends on 15)

The method of claim 15, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region (VH) having SEQ ID NO: 7, and the light chain comprising a light chain variable region (VL) having SEQ ID NO: 8.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 15)

The method of claim 15, wherein the anti-cotinine antibody has a heavy chain comprising SEQ ID NO: 9 and a light chain comprising SEQ ID NO: 10.

### Claim 26 (depends on 1)

A combination comprising the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof.

### Claim 27 (depends on 26)

The combination of claim 26, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a CDR1 having SEQ ID NO: 1, a CDR2 having SEQ ID NO: 2, and a CDR3 having SEQ ID NO: 3, and the light chain comprising a CDR1 having SEQ ID NO: 4, a CDR2 having SEQ ID NO: 5, and a CDR3 having SEQ ID NO: 6.

### Claim at position 28

28-31. (canceled)
